<DOC>
	<DOCNO>NCT00062426</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , fluorouracil , leucovorin , capecitabine , work different way stop tumor cell divide stop grow die . Combining one drug give different combination may kill tumor cell . Monoclonal antibody , bevacizumab ( Avastin™ ) , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill deliver cancer-killing substance . It yet know regimen work well treat advanced colorectal cancer . PURPOSE : This randomized phase III trial see oxaliplatin bevacizumab work well combine either fluorouracil leucovorin capecitabine treat patient metastatic recurrent colorectal cancer .</brief_summary>
	<brief_title>Oxaliplatin Bevacizumab ( Avastin™ ) With Either Fluorouracil Leucovorin Capecitabine Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare incidence grade 3 4 toxic effect occur within first 12 week treatment 2 different schedule oxaliplatin , bevacizumab ( Avastin™ ) , leucovorin calcium , fluorouracil oxaliplatin , Avastin™ , capecitabine patient advance colorectal cancer . - Compare overall response rate , progression-free survival , time treatment failure patient treat regimen . - Compare composite toxicity regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients randomize 1 3 treatment arm . - Arm I : Patients receive bevacizumab ( Avastin™ ) IV 30-90 minute , oxaliplatin IV 2 hour , leucovorin calcium IV 2 hour day 1 fluorouracil ( 5-FU ) IV 46 hour begin day 1 . Courses repeat every 14 day absence disease progression unacceptable toxicity . - Arm II : Patients receive Avastin™ IV 30-90 minute oxaliplatin IV 2 hour day 1 15 leucovorin calcium IV 10 minute 5-FU IV 3 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Arm III : Patients receive Avastin™ IV 30-90 minute oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow 1 month , every 3 month least 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 375 patient ( 125 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Metastatic recurrent disease amenable potentially curative treatment At least 1 unidimensionally measurable lesion least 20 mm conventional technique OR least 10 mm spiral CT scan Histological cytological confirmation require solitary target lesion No CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2 time upper limit normal ( ULN ) SGPT SGOT great 3 time ULN Renal Creatinine great 1.5 time ULN Creatinine clearance least 30 mL/min Cardiovascular No myocardial infarction within past 6 month No clinical evidence congestive heart failure No unstable coronary artery disease Pulmonary No interstitial pneumonia No extensive symptomatic fibrosis lung Gastrointestinal Able tolerate oral medication No lack physical integrity upper gastrointestinal tract No malabsorption syndrome No swallow difficulty Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No concurrent serious illness No uncontrolled infection No concurrent malignancy except nonmelanoma skin cancer carcinoma situ cervix cancer patient therapy remission least 5 year No peripheral neuropathy No hypersensitivity study drug ingredients No known dihydropyrimidine dehydrogenase deficiency No medical psychiatric disorder would preclude give informed consent comply study PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent prophylactic hematopoietic growth factor therapy No prior bevacizumab ( Avastin™ ) Chemotherapy At least 6 month since prior adjuvant fluorouracil , leucovorin calcium , irinotecan No prior oxaliplatin No prior chemotherapy metastatic recurrent disease No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No concurrent radiotherapy unless control bone pain Surgery Recovered prior surgery No prior organ allografts Other More 4 week since prior investigational drug No concurrent ice mouth rinse prevention stomatitis No concurrent cold cap alopecia prevention No concurrent pyridoxine No concurrent sorivudine chemicallyrelated analogue ( e.g. , brivudine ) No concurrent chronic aspirin , nonsteroidal antiinflammatory drug , warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>